Editorial: Crosstalk between epigenetics on the development of cancer and cardiovascular disease
Front Cell Dev Biol
.
2022 Oct 20:10:1027798.
doi: 10.3389/fcell.2022.1027798.
eCollection 2022.
Authors
Donghong Zhang
1
,
Yidong Wang
2
,
Tharmarajan Ramprasath
3
,
Ping Wang
4
,
Rodolfo Negri
5
Affiliations
1
Department of Pharmacology and Chemical Biology, Winship Cancer Institute, Emory University School of Medicine, Atlanta, GA, United States.
2
School of Basic Medical Sciences, Institute of Cardiovascular Sciences, Xi'an Jiaotong University Health Science Center, Xi'an, China.
3
Center for Molecular and Translational Medicine, Georgia State University, Atlanta, GA, United States.
4
School of Medical Imaging, Tianjin Medical University, Tianjin, China.
5
Department of Biology and Biotechnology "C.Darwin", Sapienza University of Rome, Rome, Italy.
PMID:
36340040
PMCID:
PMC9632337
DOI:
10.3389/fcell.2022.1027798
No abstract available
Keywords:
cancer; cardiovascular disease; epigenetic drug; epigenetic modification; epigenetics.
Publication types
Editorial